Squamous Cell Carcinoma (Skin)

1. Clinical Overview

Summary

Cutaneous Squamous Cell Carcinoma (cSCC) is a malignant neoplasm arising from epidermal keratinocytes, representing the second most common skin cancer after basal cell carcinoma. [1] Unlike basal cell carcinoma, cSCC possesses significant metastatic potential, with overall rates of 2-5% in immunocompetent patients, rising to 8-14% in high-risk subtypes. [2,3] The tumor arises through a multi-step process of UV-induced DNA damage, chronic inflammation, or immunosuppression leading to dysplastic keratinocyte proliferation and eventual dermal invasion. Early complete surgical excision yields excellent cure rates exceeding 90%, but neglected or high-risk lesions can result in regional metastasis, distant spread, and mortality. [4]

Key Features

• Appearance: Fleshy, erythematous nodule with hyperkeratotic (scaly/crusty) surface, often ulcerated or tender
• Sites: Predominantly sun-exposed areas - face (especially nose, ears, lower lip), scalp, dorsal hands, forearms
• Precursor Lesions:
  • Actinic Keratosis (AK): Dysplastic keratinocyte proliferation confined to epidermis; approximately 0.6% annual progression to invasive SCC [5]
  • Bowen Disease: Squamous cell carcinoma in situ (SCCIS) - full-thickness epidermal dysplasia without basement membrane invasion; 3-5% progression to invasive disease [6]
• Histological Hallmarks: Invasive nests of atypical keratinocytes with variable differentiation, keratin pearl formation, intercellular bridges

Clinical Pearls

The Transplant Paradox: Solid organ transplant recipients on chronic immunosuppression exhibit a profound 65-250-fold increased risk of developing cSCC compared to the general population. [7] In this cohort, the traditional BCC:SCC ratio of 4:1 reverses to approximately 1:2-4 (SCC predominates), and tumors demonstrate more aggressive biological behavior with higher rates of local recurrence (13.4% vs 8%) and metastasis (5.2% vs 2%). [8] Calcineurin inhibitors (tacrolimus, cyclosporine) confer higher risk than mammalian target of rapamycin (mTOR) inhibitors (sirolimus, everolimus).

High-Risk Anatomic Zones:

• Ear: 11-18% metastatic risk; regional nodes include preauricular, postauricular, and cervical chains [9]
• Lip (especially lower): 13-14% metastatic risk; drains to submental and submandibular nodes [9]
• Mask Areas of Face: Central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular/postauricular, temple - designated "H-zone" requiring wider excision margins [10]

Marjolin Ulcer: Highly aggressive SCC arising in chronic wounds, burn scars, osteomyelitis sinus tracts, or sites of chronic inflammation, typically after a latency period of 10-30 years. [11] These tumors exhibit metastatic rates of 18-31% and lower 5-year survival (52-77%) due to delayed diagnosis and inherent biological aggressiveness. [12]

---

2. Epidemiology

Demographics

• Incidence: Approximately 700,000 cases annually in the United States; incidence rising 3-10% per year globally, attributed to aging populations, increased UV exposure, and improved detection. [1,13]
• Age: Peak incidence 7th-8th decade; median age at diagnosis 71 years in immunocompetent patients, 40-50 years in transplant recipients [14]
• Skin Type: Fitzpatrick phototypes I-II (fair skin, poor tanning capacity, propensity to burn) account for > 90% of cases [15]
• Gender: Male:female ratio approximately 2-3:1, likely reflecting historical patterns of occupational and recreational sun exposure [1]
• Geographic Variation: Incidence correlates inversely with latitude; highest rates in Australia (> 1000 per 100,000), intermediate in Southern Europe/USA (100-150 per 100,000), lowest in Northern Europe and Asia [16]

Risk Factors

1. Ultraviolet Radiation Exposure

• Cumulative UV Exposure: Unlike BCC (associated with intermittent intense exposure), cSCC risk correlates with total lifetime UV dose [17]
• Occupational Exposure: Farmers, construction workers, outdoor athletes demonstrate 2-5-fold increased risk [18]
• Artificial UV Sources: Tanning bed use before age 35 increases SCC risk 1.7-fold [19]

2. Immunosuppression

• Solid Organ Transplantation: 65-250-fold increased risk; cumulative incidence 40-50% at 20 years post-transplant [7]
• Chronic Lymphocytic Leukemia (CLL): 8-10-fold increased risk due to T-cell dysfunction [20]
• HIV/AIDS: 3-8-fold increased risk, inversely correlated with CD4 count [21]
• Immunosuppressive Medications: Azathioprine, cyclosporine, tacrolimus confer higher risk than biological agents

3. Chronic Inflammation and Scarring

• Burn Scars: Marjolin ulcer develops in 0.5-2% of chronic burn scars after mean latency 25-30 years [11]
• Chronic Leg Ulcers: 0.5-2% malignant transformation over years-decades [22]
• Discoid Lupus Erythematosus: Chronic scarring lesions carry SCC risk [23]
• Hidradenitis Suppurativa: Long-standing disease associated with SCC development in chronic sinus tracts [24]

4. Human Papillomavirus (HPV)

• High-Risk Subtypes: HPV-16, -18, -5, -8 detected in 30-50% of cutaneous SCC, particularly in immunosuppressed patients [25]
• Mechanism: Viral E6 and E7 oncoproteins inactivate p53 and Rb tumor suppressors, synergizing with UV damage [26]
• Epidermodysplasia Verruciformis: Rare genetic disorder with inability to clear cutaneous HPV; nearly 100% develop multiple SCCs by 3rd-4th decade [27]

5. Genetic Syndromes

• Xeroderma Pigmentosum: Defective nucleotide excision repair; > 10,000-fold increased SCC risk, median onset 8 years [28]
• Albinism: Absent melanin protection; high SCC risk in sun-exposed populations [29]
• Recessive Dystrophic Epidermolysis Bullosa: 90% cumulative lifetime risk of SCC in chronic wounds/scars by age 55 [30]

6. Chemical Carcinogens

• Arsenic: Chronic exposure (contaminated water, occupational) causes arsenical keratoses progressing to SCC [31]
• Polycyclic Aromatic Hydrocarbons: Coal tar, soot exposure (historical chimney sweep SCCs) [32]
• Psoralen Plus UVA (PUVA) Therapy: Dose-dependent SCC risk; > 250 treatments confers 5-14-fold increased risk [33]

7. Ionizing Radiation

• Therapeutic Radiation: Latency 10-60 years; SCC develops in 2-25% of irradiated fields depending on dose [34]
• Chronic Radiodermatitis: Scarring, telangiectasia, atrophy predispose to aggressive SCC [35]

---

3. Pathophysiology

Molecular Mechanisms

Ultraviolet-Induced DNA Damage UV radiation, particularly UVB (290-320 nm), induces signature "UV fingerprint" mutations characterized by C→T and CC→TT transitions at dipyrimidine sites. [36] Cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts represent the principal DNA lesions, overwhelming nucleotide excision repair mechanisms with chronic exposure. [37]

p53 Pathway Disruption Mutation of the TP53 tumor suppressor gene represents the most frequent genetic alteration in cSCC, detected in 50-90% of tumors. [38] Loss of p53 "guardian of the genome" function abrogates DNA damage checkpoints, apoptosis, and senescence, permitting clonal expansion of UV-damaged keratinocytes. Field cancerization with widespread p53-mutant keratinocyte clones precedes clinically evident SCC by years-decades. [39]

Notch Pathway Inactivation Loss-of-function mutations in NOTCH1 and NOTCH2 occur in 75-80% of cutaneous SCC, representing the second most frequently altered pathway. [40] Notch normally promotes keratinocyte differentiation and suppresses proliferation; inactivation drives dedifferentiation and sustained proliferative capacity. [41]

RAS-MAPK and PI3K-AKT Activation Activating mutations in HRAS (5-10% of SCC) and dysregulation of receptor tyrosine kinase signaling (EGFR amplification/overexpression in 30-50%) drive proliferation via MAPK and PI3K-AKT cascades. [42,43] PIK3CA gain-of-function mutations occur in 5-10% of SCC, conferring resistance to apoptosis. [44]

Immune Evasion Chronic UV exposure induces local immunosuppression via generation of regulatory T-cells, myeloid-derived suppressor cells, and secretion of immunosuppressive cytokines (IL-10, TGF-β). [45] Tumor cells upregulate PD-L1 immune checkpoint ligands (40-50% of advanced SCC), enabling evasion of cytotoxic T-cell surveillance. [46]

Epithelial-Mesenchymal Transition (EMT) High-risk SCC demonstrate molecular signatures of EMT, including loss of E-cadherin adhesion and upregulation of mesenchymal markers (vimentin, N-cadherin), facilitating invasion, metastasis, and therapeutic resistance. [47]

Histopathological Progression

Normal Epidermis → Actinic Keratosis (Grade I-III) → SCC in situ (Bowen) → Invasive SCC → Metastatic SCC

• Actinic Keratosis: Basal keratinocyte atypia with nuclear pleomorphism, hyperchromasia; confined to lower one-third (Grade I), two-thirds (Grade II), or full thickness (Grade III/SCC in situ) of epidermis [48]
• Invasive SCC: Breach of basement membrane with dermal invasion; graded by differentiation:
  • "Well-differentiated: > 75% of tumor shows squamous maturation, abundant keratin pearl formation, minimal nuclear atypia"
  • "Moderately differentiated: 25-75% squamous maturation, variable keratinization"
  • "Poorly differentiated: less than 25% maturation, marked nuclear pleomorphism, high mitotic rate, absent keratinization [49]"

---

4. Clinical Presentation

Symptoms

• Growth Characteristics: Rapid enlargement over weeks to months, contrasting with the indolent growth of BCC (months to years) [50]
• Pain or Tenderness: Present in 30-40% at presentation; uncommon in BCC, raising suspicion for SCC [51]
• Bleeding: Spontaneous ulceration with friable tissue, bleeding with minor trauma [52]
• Pruritus: Reported in 15-20% of lesions [53]
• Neurological Symptoms: Numbness, paresthesia, or weakness suggesting perineural invasion (PNI) - present in 2-5% at diagnosis but constitutes high-risk feature [54]

Signs

Primary Lesion Morphology

• Nodular Subtype (Most Common): Firm, erythematous to flesh-colored nodule with central keratotic crust or ulceration; surface may demonstrate verrucous or papillomatous texture
• Ulcerative Subtype: Central ulcer with raised, indurated, everted borders; friable base with necrotic debris
• Verrucous Subtype: Exophytic, cauliflower-like growth with hyperkeratotic surface; locally aggressive but low metastatic potential
• Superficial/Erosive Subtype: Thin, scaly plaque with erythema; mimics eczema or superficial BCC
• Keratoacanthoma Variant: Rapidly growing (4-8 weeks) dome-shaped nodule with central keratin-filled crater; historically considered self-limiting but now treated as SCC variant due to indistinguishable histology and occasional progression [55]

Surface Characteristics

• Hyperkeratosis: Thick scale, often with central keratotic plug or cutaneous horn (compacted keratin projection > 5mm height) [56]
• Induration: Firm to hard consistency on palpation, reflecting dermal invasion and stromal desmoplasia
• Fixation: Tethering to underlying fascia, muscle, or bone in deeply invasive lesions
• Bleeding/Friability: Contact bleeding, ulceration with purulent or serous exudate

Regional Lymphadenopathy

• Palpable Nodes: Present in 5-10% at initial presentation; indicates nodal metastasis in 70-85% when confirmed by fine-needle aspiration or excisional biopsy [57]
• Drainage Basins:
  • "Head/Neck Lesions: Preauricular, parotid, submandibular, cervical (levels I-V) nodes"
  • "Upper Extremity: Epitrochlear, axillary nodes"
  • "Lower Extremity: Inguinal, femoral nodes"
• In-Transit Metastases: Firm dermal or subcutaneous nodules between primary tumor and regional nodes, indicating lymphatic invasion; portends poor prognosis [58]

Perineural Invasion Clinical Signs

• Sensory Deficits: Numbness, paresthesia in distribution of affected nerve (e.g., mental nerve → lower lip/chin; infraorbital nerve → cheek)
• Motor Deficits: Facial nerve palsy (inability to close eyelid, smile asymmetry) suggests extensive PNI [59]
• Pain: Neuropathic quality, may radiate along nerve distribution [60]

---

5. Clinical Examination

Systematic Approach

Inspection (Look)

1. Lesion Size: Measure maximum diameter with ruler; > 2cm constitutes high-risk feature [61]
2. Margins: Well-demarcated vs ill-defined; irregular borders suggest infiltrative growth pattern
3. Surface: Degree of keratinization, ulceration, bleeding, exudate
4. Color: Erythematous, pink, flesh-colored, or pigmented (rare; consider collision tumor with melanocytic lesion)
5. Satellite Lesions: Additional nodules within 2cm of primary tumor edge; indicates local aggressive behavior [62]

Palpation (Feel)

1. Consistency: Firm, hard, or indurated; soft consistency raises suspicion for keratoacanthoma or well-differentiated low-risk SCC
2. Depth of Invasion: Mobile over deep structures vs fixed to fascia/periosteum/bone
3. Tenderness: Elicit pain with gentle pressure; tender lesions more likely SCC than BCC [51]

Regional Lymph Node Examination (Mandatory)

1. Head/Neck Primary:
   • Preauricular/Parotid Nodes: Palpate anterior to tragus, over parotid gland
   • Submandibular Nodes: Palpate inferior to mandible, medial to angle
   • Cervical Nodes: Systematic examination of levels I-V (submental, submandibular, upper jugular, mid jugular, lower jugular, posterior triangle, prevertebral)
2. Extremity Primary: Palpate epitrochlear (medial elbow), axillary (upper limb), or inguinal (lower limb) nodes
3. Nodal Characteristics: Size (> 1cm suspicious), consistency (hard, rubbery), mobility (fixed vs mobile), tenderness

Neurological Examination (If PNI Suspected)

1. Cranial Nerves: Test facial nerve function (CN VII) - forehead wrinkling, eye closure, smile symmetry; trigeminal nerve sensory branches (CN V1-V3) - light touch sensation to forehead, cheek, chin
2. Peripheral Nerves: Test sensation in anatomic distribution corresponding to primary tumor site

Full Skin Survey

• Examine entire integument for additional premalignant (actinic keratoses) or malignant lesions; 30-50% of SCC patients develop additional primary skin cancers within 5 years [63]
• Assess for field cancerization: diffuse actinic damage, telangiectasia, dyspigmentation

---

6. Investigations

Diagnostic Workup

Dermoscopy (Non-Invasive)

• Vascular Patterns: Dotted, glomerular, or hairpin vessels (distinct from arborizing vessels of BCC) [64]
• Keratin Structures: White-yellow structureless areas, white circles corresponding to keratinization [65]
• Ulceration: Erosions, blood spots, yellowish scale-crust
• Limitation: Less specific than for BCC or melanoma; biopsy remains gold standard

Tissue Biopsy (Gold Standard)

• Excisional Biopsy: Complete removal of lesion with 1-3mm clinical margin and primary closure; preferred for small lesions (less than 1cm) allowing definitive diagnosis and treatment in single procedure [66]
• Incisional/Punch Biopsy: 3-6mm punch of most suspicious area (thickest, most indurated region); appropriate for large lesions (> 2cm) requiring confirmation before definitive wide excision or Mohs surgery [67]
• Shave Biopsy: Contraindicated if SCC suspected; may transect tumor base preventing accurate depth/invasion assessment [68]

Histopathological Features Requiring Documentation

1. Differentiation Grade: Well, moderate, or poorly differentiated [49]
2. Depth of Invasion: Measured in millimeters from granular layer to deepest invasive cells; > 4mm (Clark level IV) and > 6mm (Clark level V/subcutaneous fat) represent high-risk thresholds [69]
3. Perineural Invasion (PNI): Tumor cells tracking along nerve sheaths; further classified as:
   • Focal PNI: Involvement of small nerves less than 0.1mm diameter
   • Clinical/High-Risk PNI: Named nerves ≥0.1mm or extensive involvement; requires adjuvant radiotherapy [70]
4. Lymphovascular Invasion (LVI): Tumor emboli within lymphatic or vascular channels; independent predictor of metastasis [71]
5. Tumor Margins: Distance from invasive tumor to closest inked margin; positive (less than 1mm) or close (less than 4-5mm) margins necessitate re-excision [72]
6. Tumor Thickness: Breslow thickness measured in millimeters; parallels staging system used for melanoma
7. Tumor Subtype: Identify aggressive variants:
   • Acantholytic/Adenoid SCC: Pseudoglandular spaces; higher recurrence and metastasis [73]
   • Desmoplastic SCC: Prominent stromal fibrosis; increased PNI risk [74]
   • Spindle Cell SCC: Sarcomatoid morphology; aggressive behavior [75]

Staging Investigations

Indications for Imaging [76]

• Tumor > 2cm diameter
• Depth of invasion > 4mm
• Poorly differentiated histology
• Perineural invasion (especially clinical/high-risk PNI)
• Palpable lymphadenopathy
• Bone invasion suspected (scalp SCC, ear SCC with cartilage destruction)
• Immunosuppressed patient
• Recurrent tumor

Imaging Modalities

1. High-Resolution Ultrasound + Fine-Needle Aspiration (FNA)

   • Indication: Palpable lymphadenopathy; high-risk primary tumor without palpable nodes (elective basin ultrasound) [77]
   • Technique: Grayscale and Doppler assessment; FNA of suspicious nodes (loss of fatty hilum, round shape, increased vascularity, size > 1cm)
   • Sensitivity: 75-85% for detecting nodal metastases [78]

2. Computed Tomography (CT)

   • CT Head/Neck with IV Contrast: Assess nodal disease, bone invasion, deep soft tissue extension for head/neck SCC [79]
   • CT Chest/Abdomen/Pelvis: Staging for confirmed nodal metastases (rule out distant metastases to lung, liver)
   • Limitation: Lower soft tissue resolution than MRI; radiation exposure

3. Magnetic Resonance Imaging (MRI)

   • MRI Brain + Skull Base: Gold standard for evaluating perineural invasion; demonstrates nerve thickening, enhancement, and proximal extension along trigeminal nerve (Meckel's cave), facial nerve (internal auditory canal), or other cranial nerves [80]
   • MRI Pelvis/Extremity: Soft tissue extent, nodal involvement for extremity SCC [81]
   • Contraindication: Pacemaker, metallic implants

4. Positron Emission Tomography-CT (PET-CT)

   • Indication: Staging of confirmed regional or distant metastatic disease; detection of occult metastases in high-risk patients [82]
   • Sensitivity: 82-97% for detecting nodal metastases; 93-100% for distant metastases [83]
   • Limitation: False positives (inflammation); limited spatial resolution less than 5-8mm

5. Sentinel Lymph Node Biopsy (SLNB)

   • Indication: Investigational; considered for high-risk tumors (≥2cm, ≥4mm depth, poorly differentiated, PNI+, recurrent) without clinically detectable nodes [84]
   • Technique: Intradermal technetium-99m colloid ± blue dye injection; intraoperative gamma probe identification and excision of sentinel node(s)
   • Positivity Rate: 13-18% in high-risk cohorts [85]
   • Controversy: Unclear therapeutic benefit; prospective randomized trials lacking [86]

Laboratory Investigations

• Routine Bloodwork: Not typically indicated for localized disease
• Renal/Hepatic Function: Baseline prior to systemic therapy (chemotherapy, immunotherapy)
• HIV Testing: Consider in young patients (less than 50 years) with aggressive or multifocal SCC [87]

---

7. Management

Risk Stratification (Brigham and Women's Hospital - BWH System) [88]

Low Risk (0 risk factors)

• Tumor size less than 2cm
• Invasion depth less than 4mm (T1)
• No poorly differentiated histology
• No perineural invasion
• No lymphovascular invasion
• Metastatic Risk: less than 5%

High Risk (≥1 risk factor)

• Tumor diameter ≥2cm
• Invasion depth ≥4mm or invasion beyond subcutaneous fat (T2a) or bone invasion (T3)
• Poorly differentiated histology
• Perineural invasion (focal or clinical)
• Lymphovascular invasion present
• Metastatic Risk: 15-25% [89]

Additional High-Risk Factors (Clinical)

• Location: Ear, non-hair-bearing lip, genitalia, hands, feet
• Recurrent tumor (prior incomplete excision)
• Immunosuppression
• Rapidly growing tumor (less than 3 months to double)
• Arising in chronic scar/inflammation (Marjolin ulcer)
• Aggressive histologic subtypes (acantholytic, desmoplastic, spindle cell)

Management Algorithm

         CLINICALLY SUSPICIOUS KERATOTIC/ULCERATED LESION
                           ↓
                 DERMATOLOGY REFERRAL
           (2-Week Wait if SCC suspected in UK)
                           ↓
              BIOPSY CONFIRMS INVASIVE SCC
                           ↓
                  RISK STRATIFICATION
         ┌────────────────┴────────────────┐
      LOW RISK                         HIGH RISK
   (BWH T1, Well diff,             (BWH T2a/T3, Poor diff,
    No PNI/LVI, less than 2cm)              PNI+, LVI+, ≥2cm, High-risk site)
         ↓                                 ↓
   SURGICAL EXCISION              MULTIDISCIPLINARY TEAM (MDT)
   (4-6mm clinical margins)       DISCUSSION + STAGING IMAGING
   +/- MOHS (facial)                       ↓
         ↓                          TREATMENT PLAN
   HISTOLOGY: Margins clear?        ┌──────┴──────┐
   ├─ YES → Surveillance          LOCALIZED    NODAL/METASTATIC
   └─ NO → Re-excision            DISEASE      DISEASE
            or XRT                    ↓            ↓
                               WIDE EXCISION  RADICAL RESECTION
                               (6-10mm margins) + LYMPHADENECTOMY
                               +/- MOHS Surgery +/- ADJUVANT XRT
                               +/- ADJUVANT XRT +/- SYSTEMIC Rx
                                                (Cemiplimab, etc.)

Surgical Management (Standard of Care)

1. Standard Excision

• Low-Risk Tumors: 4-6mm clinical margin (measured from visible tumor edge to incision line) achieves 95% histological clearance [90]
• High-Risk Tumors: 6-10mm clinical margin; consider Mohs micrographic surgery for facial lesions [91]
• Depth: Excise to deep fascia (or periosteum/perichondrium for scalp/ear); ensures adequate deep margin
• Closure: Primary closure, skin graft, or local/regional flap reconstruction depending on defect size and location [92]

2. Mohs Micrographic Surgery (MMS)

• Principle: Sequential excision with immediate frozen-section margin assessment of 100% peripheral and deep margins (vs 1-5% sampling in standard "bread-loaf" histology); allows tissue-sparing with maximal margin control [93]
• Indications: [94]
  • Facial lesions in cosmetically/functionally critical areas (eyelid, nose, lip, ear)
  • High-risk features (recurrent, poorly defined margins, PNI+, aggressive histology)
  • Large tumors (> 2cm) requiring tissue conservation
• Advantages: 5-year recurrence rates 2-5% (Mohs) vs 8-10% (standard excision) for high-risk SCC [95]
• Limitations: Requires specialized training; time-intensive; higher cost; frozen artifacts may obscure poorly differentiated SCC

3. Lymph Node Dissection

• Indication: Biopsy-proven nodal metastases (FNA+ or sentinel node+) [96]
• Extent:
  • "Head/Neck: Selective neck dissection (levels I-III for submandibular/submental nodes; levels II-IV for mid-jugular nodes) or modified radical neck dissection (levels I-V) depending on extent [97]"
  • "Extremity: Superficial inguinal (lower limb) or axillary (upper limb) lymphadenectomy [98]"
• Adjuvant Radiotherapy: Recommended for extracapsular extension, multiple positive nodes (≥3), or gross residual disease [99]

4. Surgical Management of Perineural Invasion

• Focal PNI (Small Nerves less than 0.1mm): Wide excision with clear margins; adjuvant radiotherapy if high-risk features coexist [100]
• Clinical PNI (Named Nerves ≥0.1mm): Wide excision to achieve proximal and distal nerve margin clearance ± neurectomy; mandatory adjuvant radiotherapy to nerve pathway [101]

Radiotherapy

Definitive Radiotherapy (Non-Surgical Candidate)

• Indication: Patient medically unfit for surgery; patient refuses surgery; unresectable tumor (extensive bone/muscle/vascular invasion)
• Technique: Fractionated external beam radiotherapy; 50-70 Gy in 2 Gy fractions over 5-7 weeks [102]
• Tumor Control: 5-year local control 85-95% for tumors less than 2cm; 60-75% for tumors > 4cm [103]
• Complications: Acute radiodermatitis, chronic fibrosis, dyspigmentation, ulceration, radiation necrosis (5-10% risk) [104]

Adjuvant Radiotherapy (Post-Operative)

• Indications: [105]
  • Positive or close (less than 5mm) margins with re-excision not feasible
  • Perineural invasion (especially clinical/high-risk PNI)
  • Lymphovascular invasion
  • Poorly differentiated histology with other high-risk features
  • Nodal metastases with extracapsular extension or ≥2 involved nodes
  • Recurrent tumor
• Technique: 50-60 Gy to tumor bed; 60-66 Gy if gross residual disease [106]
• Outcomes: Reduces local recurrence by 30-50% in high-risk disease [107]

Systemic Therapy (Advanced/Metastatic Disease)

1. Immune Checkpoint Inhibitors (First-Line)

Cemiplimab (Anti-PD-1 Monoclonal Antibody)

• Indication: Locally advanced SCC (unresectable or contraindication to surgery/radiotherapy); metastatic SCC [108]
• Dosing: 350 mg IV every 3 weeks or 700 mg IV every 6 weeks [109]
• Efficacy: Phase II trial demonstrated objective response rate (ORR) 47-50%; median duration of response not reached at 16 months; median overall survival 25.5 months [110]
• Adverse Events: Immune-related adverse events (irAEs) in 30-40% - pneumonitis, colitis, hepatitis, thyroiditis, hypophysitis, type 1 diabetes; require corticosteroid immunosuppression and drug discontinuation for grade 3-4 toxicity [111]

Pembrolizumab (Anti-PD-1)

• Indication: Off-label use for locally advanced/metastatic SCC; FDA approval for advanced cutaneous SCC (2020) [112]
• Dosing: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
• Efficacy: ORR 34-40% in published series [113]

2. Platinum-Based Chemotherapy (Second-Line)

• Regimen: Cisplatin 75-100 mg/m² IV day 1 + 5-fluorouracil (5-FU) 1000 mg/m²/day continuous infusion days 1-4, every 21 days [114]
• Efficacy: ORR 30-50%; median progression-free survival 4-6 months [115]
• Toxicity: Myelosuppression, nephrotoxicity, ototoxicity, neuropathy, mucositis
• Limitation: No overall survival benefit demonstrated; primarily palliative intent

3. EGFR Inhibitors

• Cetuximab: Chimeric anti-EGFR monoclonal antibody; ORR 10-30% as monotherapy; combined with platinum chemotherapy or radiotherapy [116]
• Indication: Platinum-refractory disease; investigational

4. Retinoids (Chemoprevention)

• Acitretin: Oral retinoid 25-50 mg daily reduces new SCC development by 25-30% in high-risk patients (transplant recipients, xeroderma pigmentosum) [117]
• Adverse Events: Teratogenicity (contraindicated in pregnancy), xerosis, cheilitis, hypertriglyceridemia, hepatotoxicity
• Limitation: No effect on existing tumors; rebound increase in SCC upon discontinuation

5. Nicotinamide (Vitamin B3) - Chemoprevention

• Indication: Prevention of new SCC in high-risk immunocompetent patients with history of ≥2 NMSCs in past 5 years [118]
• Dosing: 500 mg orally twice daily
• Efficacy: ONTRAC trial demonstrated 30% reduction in new SCC at 12 months vs placebo [119]
• Mechanism: Enhances cellular energy metabolism, DNA repair, reduces UV-induced immunosuppression

Emerging Therapies

• Hedgehog Pathway Inhibitors: Vismodegib, sonidegib (limited efficacy in SCC; primarily for BCC) [120]
• Adoptive Cell Therapy: Tumor-infiltrating lymphocyte (TIL) expansion and reinfusion (investigational) [121]
• Intralesional Therapy: Talimogene laherparepvec (T-VEC) oncolytic virus (investigational for cutaneous SCC) [122]

---

8. Complications

Local Complications

• Recurrence: 2-5% for low-risk SCC treated with adequate excision; 8-15% for high-risk features [95]
• Tissue Destruction: Direct invasion of cartilage (ear, nose), bone (skull, facial bones), muscle, or neurovascular structures causing functional and cosmetic morbidity [123]
• Hemorrhage: Erosion into major blood vessels (carotid, facial artery) in advanced head/neck SCC [124]

Regional Metastasis

• Lymph Node Metastases: Overall 2-5%; 15-25% in high-risk SCC; 30-50% in Marjolin ulcer [2,12]
• In-Transit Metastases: Dermal/subcutaneous deposits between primary and regional nodes; indicates lymphatic invasion; 5-year survival 20-40% [58]
• Parotid Metastases: SCC of scalp, temple, or ear may metastasize to intraparotid nodes requiring parotidectomy [125]

Systemic Metastasis

• Distant Organs: Lung (most common), liver, brain, bone [126]
• Frequency: less than 1% in immunocompetent patients with localized disease; 10-15% in patients with nodal metastases [127]
• Prognosis: Median survival 7-11 months after diagnosis of distant metastases [128]

Perineural Invasion Complications

• Neuropathic Pain: Chronic pain along nerve distribution requiring multimodal analgesia [60]
• Motor Deficits: Facial nerve palsy (lagophthalmos with corneal exposure, oral incompetence); other cranial nerve palsies [59]
• Intracranial Extension: Tracking along trigeminal nerve to Meckel's cave and cavernous sinus; fatal if untreated [129]

Treatment-Related Complications

• Surgical: Wound infection, dehiscence, flap necrosis, nerve injury (sensory/motor deficits), cosmetic deformity [130]
• Radiotherapy: Radiation dermatitis, fibrosis, ectropion, dry eye, osteoradionecrosis (bone), chondroradionecrosis (ear/nose cartilage) [104]
• Immunotherapy: Immune-related adverse events (pneumonitis, colitis, hepatitis, endocrinopathies, dermatitis) requiring immunosuppression; 5-10% risk of severe grade 3-4 toxicity [111]

---

9. Prognosis and Outcomes

Survival by Stage

• Localized Disease (T1-T2a N0 M0): 5-year disease-specific survival 90-98% with appropriate surgical management [131]
• Regional Nodal Metastases (N+): 5-year survival 50-70% with surgery ± adjuvant radiotherapy [132]
• Distant Metastases (M1): Median survival 7-11 months; 5-year survival less than 10% [128]

Recurrence Risk

• Overall: 2-8% local recurrence, 2-5% nodal recurrence with standard management [133]
• High-Risk Features: 10-30% recurrence rate if ≥2 high-risk features present [134]
• Time to Recurrence: 80-90% of recurrences occur within 2 years; continued risk beyond 5 years in immunosuppressed [135]

Prognostic Factors

Favorable

• Tumor less than 2cm diameter
• Well-differentiated histology
• Depth less than 4mm
• Immunocompetent host
• Primary tumor (not recurrent)
• Complete excision with clear margins

Unfavorable

• Tumor ≥2cm (especially ≥4cm)
• Poorly differentiated or aggressive histologic subtype
• Depth ≥4mm or invasion beyond subcutaneous fat
• Perineural invasion (especially clinical PNI)
• Lymphovascular invasion
• Immunosuppression
• High-risk anatomic site (ear, lip, temple)
• Marjolin ulcer
• Positive or close margins
• Nodal metastases at presentation

---

10. Surveillance and Follow-Up

Follow-Up Schedule [136]

Low-Risk SCC

• Every 6-12 months for 5 years
• Annual full-body skin examination thereafter

High-Risk SCC

• Every 3-6 months for first 2 years
• Every 6-12 months for years 3-5
• Annual examinations thereafter
• Consider imaging (ultrasound ± CT/MRI) every 6-12 months for first 2-3 years if very high risk

Immunosuppressed Patients

• Every 3-6 months indefinitely
• Lower threshold for biopsy of new lesions
• Consider prophylactic acitretin or nicotinamide

Patient Education

• Sun Protection: Daily broad-spectrum SPF 30-50 sunscreen; protective clothing; avoid midday sun (10am-4pm) [137]
• Self-Examination: Monthly skin self-checks; report new or changing lesions promptly
• Avoid Additional UV: Discontinue tanning bed use; minimize occupational/recreational UV exposure
• Smoking Cessation: Smoking associated with 2-3-fold increased SCC risk [138]
• Immunosuppression Minimization: Transplant recipients - discuss with transplant team regarding potential conversion to lower-risk immunosuppression (e.g., calcineurin inhibitor to mTOR inhibitor) [139]

---

11. Evidence and Guidelines

Key Guidelines

Landmark Evidence

1. Mohs Surgery Efficacy

• Rowe et al. Meta-analysis (1992): Mohs micrographic surgery demonstrated 5-year recurrence rate 2.6% for primary SCC vs 8.1% for conventional excision, and 5.9% vs 23.3% for recurrent SCC. [144]

2. Immunosuppression and SCC Risk

• Hartevelt et al. (1990): Kidney transplant recipients show 65-250-fold increased SCC incidence; cumulative incidence 40% at 20 years post-transplant. [7]

3. High-Risk Features and Metastasis

• Brantsch et al. (2008): Identified tumor thickness > 6mm (HR 6.9), Clark level ≥IV (HR 6.8), and poor differentiation (HR 3.2) as independent predictors of metastasis. [145]

4. Cemiplimab Efficacy

• Migden et al. NEJM (2018): Phase II trial of cemiplimab in advanced SCC demonstrated 47% ORR in metastatic disease and 49% in locally advanced disease; median duration of response not reached at 16 months. [110]

5. Nicotinamide Chemoprevention

• Chen et al. NEJM (2015): ONTRAC trial showed nicotinamide 500mg BD reduced new SCC by 30% (RR 0.70, 95% CI 0.55-0.89) at 12 months in high-risk patients. [119]

6. Perineural Invasion Outcomes

• Ross et al. (2009): Clinical PNI (nerves ≥0.1mm) associated with 8.0-fold increased risk of local recurrence and 6.9-fold increased risk of disease-specific death compared to focal PNI. [146]

---

12. Patient and Layperson Explanation

What is Squamous Cell Carcinoma?

Squamous cell carcinoma is a skin cancer that develops from cells in the outer layer of your skin called keratinocytes. These are the cells that form the protective barrier of your skin. The cancer develops when ultraviolet (UV) light from the sun (or tanning beds) damages the DNA inside these cells over many years, causing them to grow out of control and form a tumor.

Is it dangerous?

Yes, SCC is more serious than the most common skin cancer called "basal cell carcinoma." While most SCCs can be cured if caught early, they have the ability to spread to lymph nodes (glands in your neck, armpit, or groin) or other parts of your body in about 1 in 20 to 1 in 50 cases. Certain factors make spreading more likely:

• Tumors larger than 2 centimeters (about the size of a grape)
• Tumors on the ear or lip
• Tumors that have invaded deeply into the skin
• If your immune system is weakened (such as after an organ transplant)

What does it look like?

SCC typically appears as:

• A thick, rough, scaly patch that doesn't heal
• A firm, dome-shaped bump that may have a central crater or crusted surface
• A sore or ulcer that bleeds easily and doesn't heal after several weeks
• Often tender or painful to touch (unlike other skin cancers that are usually painless)

How do we treat it?

The main treatment is surgery to cut out the cancer:

• We remove the visible tumor plus a "safety margin" of normal-looking skin around it (usually 4-10 millimeters) to ensure we remove any invisible cancer cells at the edges
• The wound is either stitched closed directly, or covered with a skin graft or flap if the area removed is large
• For cancers on the face where we want to preserve as much normal skin as possible, we may use a special technique called "Mohs surgery" where the surgeon examines the edges under a microscope during the surgery to ensure all cancer is removed while saving healthy tissue

If the cancer has grown deeply or spread to lymph nodes, we may add radiation therapy (high-energy x-rays) after surgery to kill any remaining cancer cells. For advanced cancers that cannot be removed with surgery, we may use immunotherapy drugs (cemiplimab) that help your immune system recognize and attack the cancer cells.

Will it come back?

If we remove the entire cancer with clear margins, the chance of it coming back in the same spot is low (about 2-5%). However, because your skin has been damaged by years of sun exposure, you are at higher risk (about 30-50% over 5 years) of developing new skin cancers in other areas. This is why we recommend:

• Wearing broad-spectrum sunscreen (SPF 30-50) every day, even on cloudy days
• Wearing protective clothing (wide-brimmed hat, long sleeves) when outdoors
• Avoiding the sun during peak hours (10am-4pm)
• Checking your skin monthly and reporting any new or changing spots
• Coming back for regular follow-up skin checks every 3-12 months depending on your risk

Can it be prevented?

Yes, most SCCs are preventable by protecting your skin from UV radiation throughout your life:

• Start sun protection early - damage accumulates from childhood onward
• Use sunscreen daily, reapplying every 2 hours if outdoors
• Never use tanning beds - they significantly increase your risk
• If you've had one SCC, taking a vitamin called nicotinamide (500mg twice daily) can reduce your risk of getting another by about 30%

---

13. Examination Focus

Common Exam Questions

1. Clinical Diagnosis

• Question: "A 72-year-old man presents with a tender, 1.5cm crusted nodule on the helix of his ear that has grown rapidly over 8 weeks. What is the most likely diagnosis?"
• Answer: Squamous cell carcinoma. Key features: elderly, sun-exposed site (ear helix), rapid growth, tenderness, hyperkeratotic/crusted surface. Ear SCC carries 11-18% metastatic risk.

2. High-Risk Features

• Question: "Which histopathological features of cutaneous SCC confer high risk for metastasis?"
• Answer:
  • Tumor diameter ≥2cm
  • Depth of invasion ≥4mm (Clark level IV) or ≥6mm (Clark level V/subcutaneous fat)
  • Poor histologic differentiation
  • Perineural invasion (especially clinical PNI involving nerves ≥0.1mm)
  • Lymphovascular invasion
  • Aggressive histologic subtypes (acantholytic, desmoplastic, spindle cell)

3. Immunosuppression Risk

• Question: "A 45-year-old renal transplant recipient on tacrolimus and mycophenolate presents with multiple scaly nodules on his scalp and hands. He has had 3 basal cell carcinomas excised previously. What skin cancer is he now most at risk for?"
• Answer: Squamous cell carcinoma. Solid organ transplant recipients have 65-250-fold increased SCC risk; the BCC:SCC ratio reverses from 4:1 to 1:2-4 (SCC predominates). Tumors are more aggressive with higher recurrence and metastatic rates. Consider switching immunosuppression from calcineurin inhibitor to mTOR inhibitor (sirolimus).

4. Surgical Margins

• Question: "What are the recommended surgical margins for excision of low-risk vs high-risk cutaneous SCC?"
• Answer: Low-risk SCC (well-differentiated, less than 2cm, depth less than 4mm, no PNI/LVI): 4-6mm clinical margin. High-risk SCC (poorly differentiated, ≥2cm, depth ≥4mm, PNI+, high-risk site): 6-10mm margin or Mohs micrographic surgery for facial lesions.

5. Perineural Invasion

• Question: "A 68-year-old presents with a 3cm ulcerated SCC on the left temple with numbness over the left forehead and cheek. What investigation is required and why?"
• Answer: MRI brain with focus on skull base. Numbness suggests perineural invasion along branches of the trigeminal nerve (CN V). MRI is the gold standard for demonstrating nerve involvement, tracking proximal extent along nerve to Meckel's cave/cavernous sinus, and planning surgical resection ± adjuvant radiotherapy to the nerve pathway.

6. Marjolin Ulcer

• Question: "A 65-year-old man with a 30-year-old burn scar on his lower leg develops a painful, non-healing ulcer within the scar. Biopsy shows poorly differentiated SCC. What is this entity and what is the prognosis?"
• Answer: Marjolin ulcer - SCC arising in chronic wounds or burn scars after latency period 10-30 years. These tumors are highly aggressive with metastatic rates 18-31% and 5-year survival 52-77%, poorer than de novo SCC due to delayed diagnosis and inherent biological aggressiveness. Requires wide excision and close surveillance for nodal metastases.

7. Systemic Therapy

• Question: "A 75-year-old with metastatic cutaneous SCC involving cervical lymph nodes is deemed unfit for surgery. What is the first-line systemic therapy?"
• Answer: Cemiplimab - anti-PD-1 immune checkpoint inhibitor. Phase II data showed objective response rate 47-50% in metastatic SCC with durable responses (median duration not reached at 16 months). FDA-approved 2018 for locally advanced or metastatic SCC not amenable to curative surgery/radiotherapy.

Viva Points

Keratoacanthoma vs SCC

• Keratoacanthoma: Rapidly growing (4-8 weeks) dome-shaped nodule with central keratin-filled crater; classically described as self-limiting with spontaneous resolution, but modern consensus treats as SCC variant due to:
  • Histological indistinguishability from well-differentiated SCC
  • Documented cases of progression to invasive SCC
  • Rare metastatic potential
• Management: Excision or Mohs surgery; observation no longer recommended

Perineural Invasion Classification

• Focal PNI: Involvement of small nerves less than 0.1mm diameter; managed with wide excision to clear margins; adjuvant XRT considered if other high-risk features present
• Clinical/High-Risk PNI: Named nerves ≥0.1mm diameter or radiographic evidence of nerve involvement; associated with 8-fold increased local recurrence and 7-fold increased disease-specific mortality; mandatory adjuvant radiotherapy to entire nerve pathway from tumor to skull base

Why does immunosuppression increase SCC more than BCC?

• Mechanism: SCC pathogenesis involves UV-induced DNA damage, p53 mutation, and immune surveillance escape. Immunosuppression:
  • Impairs T-cell-mediated clearance of UV-damaged keratinocytes with p53 mutations (field cancerization)
  • Reduces immunosurveillance of early SCC clones
  • Permits HPV persistence (viral oncoproteins inactivate p53, synergize with UV damage)
• BCC Pathogenesis: Driven primarily by Hedgehog pathway mutations (PTCH1, SMO); less dependent on immune surveillance, hence smaller relative risk increase with immunosuppression

Actinic Keratosis Progression

• Annual Progression Rate: 0.6% per lesion per year to invasive SCC
• Regression Rate: 15-25% spontaneous regression
• Management: Field-directed therapy (5-fluorouracil cream, imiquimod, photodynamic therapy) for multiple lesions; cryotherapy for isolated lesions; reduces progression to SCC

Sentinel Lymph Node Biopsy Controversy

• Rationale: Identify occult nodal metastases in high-risk SCC to guide adjuvant therapy
• Evidence: SLNB positivity 13-18% in high-risk cohorts; positive SLNB associated with worse prognosis
• Controversy: No randomized trial demonstrating therapeutic benefit (survival improvement); false-negative rate 10-20%; risk of lymphedema (5-10%); not standard of care but may be considered in select high-risk patients as part of clinical trial or MDT discussion

---

14. References

Primary Sources

1. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957-966. doi:10.1016/j.jaad.2012.11.037

2. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713-720. doi:10.1016/S1470-2045(08)70178-5

3. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(4):419-428. doi:10.1001/jamadermatol.2015.4994

4. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975-983. doi:10.1056/NEJM200103293441306

5. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169(3):502-518. doi:10.1111/bjd.12420

6. Lohmann CM, Solomon AR. Clinicopathologic variants of cutaneous squamous cell carcinoma. Adv Anat Pathol. 2001;8(1):27-36. doi:10.1097/00125480-200101000-00004

7. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49(3):506-509. doi:10.1097/00007890-199003000-00006

8. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691. doi:10.1056/NEJMra022137

9. Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115(5):870-875. doi:10.1097/01.MLG.0000158349.64740.81

10. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241-248. doi:10.1016/0190-9622(92)70178-i

11. Chalya PL, Mabula JB, Rambau PF, et al. Marjolin's ulcers at Bugando Medical Centre in northwestern Tanzania: a retrospective review of 64 cases. World J Surg Oncol. 2012;10:38. doi:10.1186/1477-7819-10-38

12. Copcu E, Aktas A, Sişman N, Öztan Y. Thirty-one cases of Marjolin's ulcer. Clin Exp Dermatol. 2003;28(2):138-141. doi:10.1046/j.1365-2230.2003.01207.x

13. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081-1086. doi:10.1001/jamadermatol.2015.1187

14. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1-17. doi:10.1067/mjd.2002.125579

15. Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006;55(5):741-760. doi:10.1016/j.jaad.2005.08.063

16. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-1080. doi:10.1111/j.1365-2133.2012.10830.x

17. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63(1-3):8-18. doi:10.1016/s1011-1344(01)00198-1

18. Rosso S, Zanetti R, Martinez C, et al. The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer. 1996;73(11):1447-1454. doi:10.1038/bjc.1996.275

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current local guidelines. This content reflects evidence available as of January 2026.